170 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study.

Authors :: Griese, M.
Tullis, E.
Chilvers, M.
Fabrizzi, B.
Jain, R.
Legg, J.
Mall, M.
McKone, E.
Polineni, D.
Poplawska, K.
Robinson, P.
Taylor-Cousar, J.
Ahluwalia, N.
Doolittle, C.
Jennings, M.
Moskowitz, S.
Prieto-Centurion, V.
Tan, Y.V.
Tian, S.
Vinarsky, V.
Source :: Journal of Cystic Fibrosis. 2022 Supplement 2, Vol. 21, pS99-S100. 2p.
Publication Year :: 2022

Full Text Access

Tools